0001209191-21-010882.txt : 20210216 0001209191-21-010882.hdr.sgml : 20210216 20210216174905 ACCESSION NUMBER: 0001209191-21-010882 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210211 FILED AS OF DATE: 20210216 DATE AS OF CHANGE: 20210216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ordonez Claudia CENTRAL INDEX KEY: 0001808290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39264 FILM NUMBER: 21641393 MAIL ADDRESS: STREET 1: C/O KEROS THERAPEUTICS, INC. STREET 2: 99 HAYDEN AVENUE, SUITE 120, BUILDING E CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Keros Therapeutics, Inc. CENTRAL INDEX KEY: 0001664710 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E) STREET 2: LEDGEMONT TECHNOLOGY CENTER CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-513-8774 MAIL ADDRESS: STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E) STREET 2: LEDGEMONT TECHNOLOGY CENTER CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-11 0 0001664710 Keros Therapeutics, Inc. KROS 0001808290 Ordonez Claudia C/O KEROS THERAPEUTICS, INC. 99 HAYDEN AVENUE, SUITE 120, BUILDING E LEXINGTON MA 02421 0 1 0 0 Chief Medical Officer Common Stock 2021-02-11 4 M 0 1000 0.48 A 1000 D Common Stock 2021-02-11 4 S 0 175 63.10 D 825 D Common Stock 2021-02-11 4 S 0 312 64.17 D 513 D Common Stock 2021-02-11 4 S 0 216 65.35 D 297 D Common Stock 2021-02-11 4 S 0 295 66.19 D 2 D Common Stock 2021-02-11 4 S 0 2 68.05 D 0 D Employee Stock Option (right to buy) 0.48 2021-02-11 4 M 0 1000 0.00 D 2029-09-18 Common Stock 1000 102211 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.71 to $63.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.775 to $64.535 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.855 to $65.73 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.00 to $66.69 inclusive. One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. /s/ Keith Regnante, Attorney-in-Fact 2021-02-16